牛牛AI助理已提取核心訊息
On January 11, 2024, Adial Pharmaceuticals, Inc., a Delaware-incorporated company listed on NASDAQ under the trading symbols ADIL and ADILW for its common stock and warrants respectively, held a Special Meeting of Stockholders. During this meeting, stockholders voted on two key proposals. The first proposal, known as the Warrant Exercise Proposal, sought approval for the issuance of up to 3,007,092 shares of common stock upon the exercise of warrants related to a private placement offering that concluded on October 24, 2023. This issuance could potentially exceed 20% of the company's outstanding common stock prior to the offering. The proposal received approval with 432,915 votes in favor, 51,550 against, and 6,621 abstentions. The second proposal, the Adjournment Proposal, was to approve the adjournment of the Special Meeting to...Show More
On January 11, 2024, Adial Pharmaceuticals, Inc., a Delaware-incorporated company listed on NASDAQ under the trading symbols ADIL and ADILW for its common stock and warrants respectively, held a Special Meeting of Stockholders. During this meeting, stockholders voted on two key proposals. The first proposal, known as the Warrant Exercise Proposal, sought approval for the issuance of up to 3,007,092 shares of common stock upon the exercise of warrants related to a private placement offering that concluded on October 24, 2023. This issuance could potentially exceed 20% of the company's outstanding common stock prior to the offering. The proposal received approval with 432,915 votes in favor, 51,550 against, and 6,621 abstentions. The second proposal, the Adjournment Proposal, was to approve the adjournment of the Special Meeting to a later date if necessary. However, this was not required as the Warrant Exercise Proposal passed without the need for further solicitation of votes. The Adjournment Proposal also passed with 436,338 votes in favor, 47,809 against, and 6,939 abstentions. The results of the meeting were filed with the SEC and are detailed in the company's definitive proxy statement.
2024年1月11日，在納斯達克上市的特拉華州註冊公司Adial Pharmicals, Inc. 舉行了股東特別會議，其普通股和認股權證的交易代碼分別爲ADIL和ADILW。在這次會議上，股東對兩項關鍵提案進行了投票。第一項提案，即認股權證行使提案，尋求批准在行使與2023年10月24日結束的私募發行相關的認股權證後，最多發行3,007,092股普通股。此次發行可能會超過公司發行前已發行普通股的20％。該提案以432,915票贊成，51,550票反對，6,621票棄權獲得批准。第二項提案，即休會提議，是批准在必要時將特別會議休會。但是，這不是必需的，因爲認股權證行使提案無需進一步徵集投票即獲得通過。休會提案也以436,338票贊成、47,809票反對和6,939票棄權獲得通過。會議結果已提交給美國證券交易委員會，並在公司的最終委託書中進行了詳細說明。
2024年1月11日，在納斯達克上市的特拉華州註冊公司Adial Pharmicals, Inc. 舉行了股東特別會議，其普通股和認股權證的交易代碼分別爲ADIL和ADILW。在這次會議上，股東對兩項關鍵提案進行了投票。第一項提案，即認股權證行使提案，尋求批准在行使與2023年10月24日結束的私募發行相關的認股權證後，最多發行3,007,092股普通股。此次發行可能會超過公司發行前已發行普通股的20％。該提案以432,915票贊成，51,550票反對，6,621票棄權獲得批准。第二項提案，即休會提議，是批准在必要時將特別會議休會。但是，這不是必需的，因爲認股權證行使提案無需進一步徵集投票即獲得通過。休會提案也以436,338票贊成、47,809票反對和6,939票棄權獲得通過。會議結果已提交給美國證券交易委員會，並在公司的最終委託書中進行了詳細說明。
有用
沒用